نتائج البحث - "Corran Roberts"

1

Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours

المؤلفون: Sylwia Kopijasz, Corran Roberts, Victoria Y Strauss, Shibani Nicum, Andrew R Clamp, Marcia Hall, Richard D. Kennedy, Ana Montes, Charlie Gourley, Jacinta Abraham, Michael R.L. Stratford, Susana Banerjee, Lisa K. Folkes

المصدر: Roberts, C, Strauss, V Y, Kopijasz, S, Gourley, C, Hall, M, Montes, A, Abraham, J, Clamp, A, Kennedy, R, Banerjee, S, Folkes, L K, Stratford, M & Nicum, S 2020, ' Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours ', British Journal of Cancer, vol. 122, no. 4, pp. 483-490 . https://doi.org/10.1038/s41416-019-0674-4Test, https://doi.org/10.1038/s41416-019-0674-4Test
Roberts, C, Strauss, V Y, Kopijasz, S, Gourley, C, Hall, M, Montes, A, Abraham, J, Clamp, A, Kennedy, R, Banerjee, S, Folkes, L K, Stratford, M & Nicum, S 2020, ' Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours ', British Journal of Cancer, vol. 122, no. 4, pp. 483-490 . https://doi.org/10.1038/s41416-019-0674-4Test
British Journal of Cancer

مصطلحات موضوعية: Adult, Oncology, medicine.medical_specialty, Cancer Research, Cancer therapy, medicine.medical_treatment, Breast Neoplasms, Gene mutation, Article, 03 medical and health sciences, 0302 clinical medicine, Breast cancer, SDG 3 - Good Health and Well-being, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Humans, Medicine, Aged, 030304 developmental biology, BRCA2 Protein, Ovarian Neoplasms, Salvage Therapy, Cisplatin, 0303 health sciences, Chemotherapy, BRCA1 Protein, Mercaptopurine, business.industry, Middle Aged, medicine.disease, Progression-Free Survival, Cancer therapeutic resistance, Methotrexate, Drug Resistance, Neoplasm, 030220 oncology & carcinogenesis, PARP inhibitor, Female, Neoplasm Recurrence, Local, business, Ovarian cancer, medicine.drug

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2b494bdec4a88dbce8776a6e9b65b9cTest
https://doi.org/10.1038/s41416-019-0674-4Test

2

A phase II open label, randomised study of ipilimumab with temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: the Ipi-Glio trial protocol

المؤلفون: Jane Holmes, Leena Elhussein, Claire Brooks, Tim Maughan, Corran Roberts, Tim Coutts, S.M. Ng, Nicholas F. Brown, Peter Hoskin, Paul Mulholland, Sarah P. Blagden

المصدر: BMC Cancer
Brown, N F, Ng, S M, Brooks, C, Coutts, T, Holmes, J, Roberts, C, Elhussein, L, Hoskin, P, Maughan, T, Blagden, S & Mulholland, P 2020, ' A phase II open label, randomised study of ipilimumab with temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma : The Ipi-Glio trial protocol ', BMC Cancer, vol. 20, no. 1, 198 . https://doi.org/10.1186/s12885-020-6624-yTest
BMC Cancer, Vol 20, Iss 1, Pp 1-5 (2020)

مصطلحات موضوعية: 0301 basic medicine, Adult, Male, Cancer Research, medicine.medical_specialty, Ipilimumab, lcsh:RC254-282, 03 medical and health sciences, Study Protocol, Young Adult, 0302 clinical medicine, Surgical oncology, Glioma, Genetics, medicine, Temozolomide, Humans, Adverse effect, Aged, Manchester Cancer Research Centre, business.industry, Brain Neoplasms, Standard treatment, ResearchInstitutes_Networks_Beacons/mcrc, Chemoradiotherapy, Cytoreduction Surgical Procedures, Middle Aged, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, Debulking, Survival Analysis, United Kingdom, Surgery, 030104 developmental biology, Treatment Outcome, Oncology, 030220 oncology & carcinogenesis, Female, business, Glioblastoma, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b75e328f376518aaf00b055e9ba51b3Test
http://europepmc.org/articles/PMC7068928Test

3

Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular Signature

المصدر: Craddock, C, Houlton, A E, Quek, L S, Ferguson, P, Gbandi, E, Roberts, C, Metzner, M, Garcia-Martin, N, Kennedy, A, Hamblin, A, Raghavan, M, Nagra, S, Dudley, L, Wheatley, K, McMullin, M, Pillai, S P, kelly, R J, Siddique, S, Dennis, M, Cavenagh, J D & Vyas, P 2017, ' Outcome of azacitidine therapy in acute myeloid leukaemia is not improved by concurrent vorinostat therapy but is predicted by a diagnostic molecular signature ', Clinical Cancer Research . https://doi.org/10.1158/1078-0432.CCR-17-1423Test

مصطلحات موضوعية: Adult, Male, 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Myeloid, Azacitidine, Hydroxamic Acids, Disease-Free Survival, Drug Administration Schedule, 03 medical and health sciences, 0302 clinical medicine, Immunophenotyping, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Cyclin-Dependent Kinase Inhibitor p18, Humans, Progenitor cell, neoplasms, Vorinostat, Cyclin-Dependent Kinase Inhibitor p16, Aged, business.industry, Cancer, Myeloid leukemia, Middle Aged, medicine.disease, Combined Modality Therapy, Isocitrate Dehydrogenase, Histone Deacetylase Inhibitors, Leukemia, Myeloid, Acute, Leukemia, Treatment Outcome, Editorial, 030104 developmental biology, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Mutation, Immunology, Female, Tumor Suppressor Protein p53, business, medicine.drug